Anti Inflammatory News and Research

RSS

MorphoSys and Proteros Biostructures receive research grant to develop new technology platform for structure-based engineering of antibodies

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Proteros Biostructures announced today that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural characterization of antibody-antigen-complexes.

12 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Research-based tip sheets provide details on breast cancer

Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship.

11 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

Cytomedix secures $13 million in registered direct offering under equity purchase agreements

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today that the Company has secured approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements.

11 Oct 2010

Chelsea Therapeutics announces underwriters exercise 1.07 million additional shares to cover over-allotments

Chelsea Therapeutics International, Ltd. has completed its previously announced public offering of common stock and announced that the underwriters exercised their option to purchase approximately 1.07 million additional shares to cover over-allotments.

7 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen Idec today announced that more than 45 company and partner-sponsored platform and poster presentations will be presented during the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden, October 13 - 16, 2010.

6 Oct 2010

Saneron receives grant to develop safety guidelines for transplanting HUBC cells in Alzheimer's disease

The National Institutes of Health has awarded a three-year, $2.6-million grant to the University of South Florida and Tampa-based biotechnology company Saneron-CCEL Therapeutics, Inc., to establish dosing and safety guidelines for transplanting human umbilical cord blood cells (HUBC) into animal models of Alzheimer's disease.

6 Oct 2010

Fish oil induces severe colitis and colon cancer in mice

Fish oil - long encouraged by doctors as a supplement to support heart and joint health, among other benefits - induced severe colitis and colon cancer in mice in research led by Michigan State University and published this month in the journal Cancer Research.

6 Oct 2010

ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain

ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.

5 Oct 2010

Study could lead to new therapies for acute muscle injury

A new research study published in The FASEB Journal may change how sports injuries involving muscle tissue are treated, as well as how much patient monitoring is necessary when potent anti-inflammatory drugs are prescribed for a long time. That's because the study shows for the first time that inflammation actually helps to heal damaged muscle tissue, turning conventional wisdom on its head that inflammation must be largely controlled to encourage healing.

5 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Walnuts and walnut oil reduce blood pressure during stress: Study

A diet rich in walnuts and walnut oil may prepare the body to deal better with stress, according to a team of Penn State researchers who looked at how these foods, which contain polyunsaturated fats, influence blood pressure at rest and under stress.

4 Oct 2010

Sulindac drug derivative effective in preventing colon cancer: Research

Researchers in the Division of Cancer Prevention, Department of Medicine, at Stony Brook University have discovered that a novel derivative of sulindac, a non-steroidal anti-inflammatory drug (NSAID) known to prevent colon cancer, is more effective and safer than sulindac in preventing colon cancer in animals. The study results are reported in the October issue of the journal Gastroenterology.

3 Oct 2010

Chelsea prices common stock public offering

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.

1 Oct 2010

Study suggests H2O2 can act as anti-inflammatory compound

A major blow to the free radical theory of aging, which had lead the research in aging for more than 50 years and fuels a multimillionaire anti-aging industry has just been published by Portuguese scientists from the University of Minho. According to the theory, free radicals provoke oxidative damage and this is the cause of aging.

30 Sep 2010

Tobira completes $31 million Series B financing

Tobira Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease, today announced the completion of a $31 million Series B financing. New investor Novo A/S is leading the round, joined by original investors, Domain Associates, L.L.C., Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

30 Sep 2010

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Bbiotechnology company NEUROKIN, dedicated to the development of neuroprotective drugs to treat acute neurological diseases, announces today that the European Patent Office (EPO) has granted patent EP 1998778 protecting the use of NK-102, its most advanced drug candidate. This first European award constitutes an important milestone for NEUROKIN. An application for registration is under way in Brazil, Canada, China, USA and Japan.

29 Sep 2010

Anti Inflammatory News and Research

MorphoSys and Proteros Biostructures receive research grant to develop new technology platform for structure-based engineering of antibodies

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Research-based tip sheets provide details on breast cancer

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Cytomedix secures $13 million in registered direct offering under equity purchase agreements

Chelsea Therapeutics announces underwriters exercise 1.07 million additional shares to cover over-allotments

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Saneron receives grant to develop safety guidelines for transplanting HUBC cells in Alzheimer's disease

Fish oil induces severe colitis and colon cancer in mice

ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain

Study could lead to new therapies for acute muscle injury

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Walnuts and walnut oil reduce blood pressure during stress: Study

Sulindac drug derivative effective in preventing colon cancer: Research

Chelsea prices common stock public offering

Study suggests H2O2 can act as anti-inflammatory compound

Tobira completes $31 million Series B financing

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News